IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0089168.html
   My bibliography  Save this article

Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review

Author

Listed:
  • Bikaramjit S Mann
  • Lianne Barnieh
  • Karen Tang
  • David J T Campbell
  • Fiona Clement
  • Brenda Hemmelgarn
  • Marcello Tonelli
  • Diane Lorenzetti
  • Braden J Manns

Abstract

Background: Prescription drugs are used in people with hypertension, diabetes, and cardiovascular disease to manage their illness. Patient cost sharing strategies such as copayments and deductibles are often employed to lower expenditures for prescription drug insurance plans, but the impact on health outcomes in these patients is unclear. Objective: To determine the association between drug insurance and patient cost sharing strategies on medication adherence, clinical and economic outcomes in those with chronic diseases (defined herein as diabetes, hypertension, hypercholesterolemia, coronary artery disease, and cerebrovascular disease). Methods: Studies were included if they examined various cost sharing strategies including copayments, coinsurance, fixed copayments, deductibles and maximum out-of-pocket expenditures. Value-based insurance design and reference based pricing studies were excluded. Two reviewers independently identified original intervention studies (randomized controlled trials, interrupted time series, and controlled before-after designs). MEDLINE, EMBASE, Cochrane Library, CINAHL, and relevant reference lists were searched until March 2013. Two reviewers independently assessed studies for inclusion, quality, and extracted data. Eleven studies, assessing the impact of seven policy changes, were included: 2 separate reports of one randomized controlled trial, 4 interrupted time series, and 5 controlled before-after studies. Findings: Outcomes included medication adherence, clinical events (myocardial infarction, stroke, death), quality of life, healthcare utilization, or cost. The heterogeneity among the studies precluded meta-analysis. Few studies reported the impact of cost sharing strategies on mortality, clinical and economic outcomes. The association between patient copayments and medication adherence varied across studies, ranging from no difference to significantly lower adherence, depending on the amount of the copayment. Conclusion: Lowering cost sharing in patients with chronic diseases may improve adherence, but the impact on clinical and economic outcomes is uncertain.

Suggested Citation

  • Bikaramjit S Mann & Lianne Barnieh & Karen Tang & David J T Campbell & Fiona Clement & Brenda Hemmelgarn & Marcello Tonelli & Diane Lorenzetti & Braden J Manns, 2014. "Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-8, March.
    • Handle: RePEc:plo:pone00:0089168
    DOI: 10.1371/journal.pone.0089168
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089168
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089168&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0089168?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Huttin, Christine, 1994. "The use of prescription charges," Health Policy, Elsevier, vol. 27(1), pages 53-73, January.
    2. Piette, J.D. & Heisler, M. & Wagner, T.H., 2004. "Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk," American Journal of Public Health, American Public Health Association, vol. 94(10), pages 1782-1787.
    3. Liu, Shuen-Zen & Romeis, James C., 2004. "Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly," Health Policy, Elsevier, vol. 68(3), pages 277-287, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Laba, Tracey-Lea & Cheng, Lucy & Worthington, Heather C. & McGrail, Kimberlyn M. & Chan, Fiona K.I. & Mamdani, Muhammad & Law, Michael R., 2020. "What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan," Health Policy, Elsevier, vol. 124(9), pages 977-983.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Piette, John D. & Heisler, Michele & Horne, Robert & Caleb Alexander, G., 2006. "A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures," Social Science & Medicine, Elsevier, vol. 62(4), pages 846-857, February.
    2. Lundberg, Lena & Johannesson, Magnus & Isacson, Dag G. L. & Borgquist, Lars, 1998. "Effects of user charges on the use of prescription medicines in different socio-economic groups," Health Policy, Elsevier, vol. 44(2), pages 123-134, May.
    3. Zhu, Minmin & Dib, Hassan H. & Zhang, Xinping & Tang, Shengchun & Liu, Liqun, 2008. "The influence of health insurance towards accessing essential medicines: The experience from Shenzhen labor health insurance," Health Policy, Elsevier, vol. 88(2-3), pages 371-380, December.
    4. Borrescio-Higa, Florencia, 2015. "Can Walmart make us healthier? Prescription drug prices and health care utilization," Journal of Health Economics, Elsevier, vol. 44(C), pages 37-53.
    5. Rättö, Hanna & Kurko, Terhi & Martikainen, Jaana E. & Aaltonen, Katri, 2021. "The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis," Health Policy, Elsevier, vol. 125(9), pages 1166-1172.
    6. Bakker, F. M. & van Vliet, R. C. J. A., 1995. "The introduction of deductibles for prescription drugs in a national health insurance: compulsory or voluntary?," Health Policy, Elsevier, vol. 31(1), pages 53-65, January.
    7. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    8. Christine Huttin, 1997. "Income distribution and consumer demand for health services. The case of prescribed medicines in the USA," Applied Economics, Taylor & Francis Journals, vol. 29(4), pages 497-503.
    9. Sarma, Sisira & Basu, Kisalaya & Gupta, Anil, 2007. "The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada," Social Science & Medicine, Elsevier, vol. 65(12), pages 2553-2565, December.
    10. Galina Besstremyannaya, 2014. "Heterogeneous effect of coinsurance rate on healthcare costs: generalized finite mixtures and matching estimators," Discussion Papers 14-014, Stanford Institute for Economic Policy Research.
    11. Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen, 2006. "Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003," PharmacoEconomics, Springer, vol. 24(9), pages 891-902, September.
    12. Vincenzo Atella & Peter R. Noyce & Ellen Schafheutle & Karen Hassell, 2005. "Affordability of Medicines and Patients' Cost Reduction Behaviors: Empirical Evidence Based on SUR Estimates from Italy and the United Kingdom," CEIS Research Paper 71, Tor Vergata University, CEIS.
    13. Florencia Borrescio, 2014. "Can Walmart make us healthier? The effect of Market Forces on Health Care Utilization," Working Papers wp_042, Adolfo Ibáñez University, School of Government.
    14. Martin Chalkley;Ray Robinson, 1997. "Theory and Evidence on Cost Sharing in Health Care: An Economic Perspective," Monograph 000429, Office of Health Economics.
    15. Katherine Baird, 2016. "The Financial Burden of Out-of-Pocket Expenses in the US and Canada: How Different is the US?," LIS Working papers 671, LIS Cross-National Data Center in Luxembourg.
    16. Christine Huttin, 2000. "A cluster analysis on income elasticity variations and US pharmaceutical expenditures," Applied Economics, Taylor & Francis Journals, vol. 32(10), pages 1241-1247.
    17. Faden, Laura & Vialle-Valentin, Catherine & Ross-Degnan, Dennis & Wagner, Anita, 2011. "Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence," Health Policy, Elsevier, vol. 100(2), pages 134-143.
    18. Schumacher, Heiner, 2016. "Insurance, self-control, and contract flexibility," European Economic Review, Elsevier, vol. 83(C), pages 220-232.
    19. Bakker, Frank M. & van Vliet, Rene C. J. A. & van de Ven, Wynand P. M. M., 2000. "Deductibles in health insurance: can the actuarially fair premium reduction exceed the deductible?," Health Policy, Elsevier, vol. 53(2), pages 123-141, September.
    20. Noyce, Peter R. & Huttin, Christine & Atella, Vicenzo & Brenner, Gerhard & Haaijer-Ruskamp, Flora M. & Hedvall, Maj-Britt & Mechtler, Reli, 2000. "The cost of prescription medicines to patients," Health Policy, Elsevier, vol. 52(2), pages 129-145, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0089168. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.